3,5-dimethoxycinnamic acid: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5324677 |
| CHEMBL ID | 1436594 |
| SCHEMBL ID | 290940 |
| MeSH ID | M0084648 |
| Synonym |
|---|
| AC-16565 |
| LS-13949 |
| EN300-14795 |
| 20767-04-8 |
| 3,5-dimethoxycinnamic acid |
| nsc-359855 |
| 16909-11-8 |
| nsc359855 |
| inchi=1/c11h12o4/c1-14-9-5-8(3-4-11(12)13)6-10(7-9)15-2/h3-7h,1-2h3,(h,12,13)/b4-3 |
| 3,5-dimethoxycinnamic acid, predominantly trans, >=99% |
| smr000639211 |
| MLS001075636 |
| 5C07E274-24F8-4332-9F24-971728297C05 |
| AKOS000212152 |
| (e)-3-(3,5-dimethoxyphenyl)prop-2-enoic acid |
| 3-(3,5-dimethoxyphenyl)acrylic acid |
| (2e)-3-(3,5-dimethoxyphenyl)prop-2-enoic acid |
| STK893296 |
| 3-(3,5-dimethoxyphenyl)prop-2-enoic acid |
| (e)-3-(3,5-dimethoxyphenyl)prop-2-enoate;3,5-dimethoxycinnamic acid |
| A811055 |
| NCGC00247447-01 |
| 2-propenoic acid, 3-(3,5-dimethoxyphenyl)- |
| HMS2196B04 |
| trans-3,5-dimethoxycinnamic acid |
| (e)-3-(3,5-dimethoxyphenyl)acrylic acid |
| 2-propenoic acid, 3-(3,5-dimethoxyphenyl)-, (2e)- |
| BBL020607 |
| SCHEMBL290940 |
| J-501885 |
| cinnamic acid, 3,5-dimethoxy- |
| CHEMBL1436594 |
| mfcd00004389 |
| 3,5-dimethoxycinnamic acid, predominantly trans |
| AS-14516 |
| Q63395431 |
| 3-(3,5-dimethoxyphenyl)acrylicacid |
| AMY39426 |
| EN300-34435 |
| CS-0150473 |
| CS-0368600 |
| DTXSID601251999 |
| (2e)-3-(3,5-dimethoxyphenyl)-2-propenoic acid |
| Z104510540 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 0.2818 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| ClpP | Bacillus subtilis | Potency | 31.6228 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 39.8107 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 7.9433 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 0.7079 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 25.1189 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 3.6626 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| snurportin-1 | Homo sapiens (human) | Potency | 3.6626 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 3.6626 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| geminin | Homo sapiens (human) | Potency | 0.3836 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| RNA polymerase II cis-regulatory region sequence-specific DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| double-stranded DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| RNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| mRNA 3'-UTR binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| lipid binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| identical protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| pre-mRNA intronic binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| molecular condensate scaffold activity | TAR DNA-binding protein 43 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| intracellular non-membrane-bounded organelle | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleus | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
| perichromatin fibrils | TAR DNA-binding protein 43 | Homo sapiens (human) |
| mitochondrion | TAR DNA-binding protein 43 | Homo sapiens (human) |
| cytoplasmic stress granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nuclear speck | TAR DNA-binding protein 43 | Homo sapiens (human) |
| interchromatin granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
| chromatin | TAR DNA-binding protein 43 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.06) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||